CANSPAR

Community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis

Oral Community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis Adult: 100-300 mg daily, as a single dose or 2 divided doses. Renal impairment: Dosage adjustment may be necessary in severe impairment.

May be taken with or without food.

Hypersensitivity; pregnancy and lactation; children <18 yr.

Hypersensitivity; pregnancy and lactation; children <18 yr.

Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia. Potentially Fatal: AV block; anaphylaxis.

Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin. Potentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole,terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.

Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp. Absorption: Well absorbed from the GI tract (oral); peak plasma concentrations after 3-6 hr. Distribution: Widely distributed into tissues including respiratory tissues. Protein-binding: 45%. Metabolism: Hepatic (by glucuronidation). Excretion: Excreted in equal amounts in the urine and faeces as unchanged drug and glucuronide metabolites; elimination half-life: 20 hr.

Quinolones

J01MA09 - sparfloxacin; Belongs to the class of quinolones, fluoroquinolone. Used in the treatment of systemic infections.

*sparfloxacin information: Note that there are some more drugs interacting with sparfloxacin sparfloxacin sparfloxacin brands available in India Always prescribe with Generic Name : sparfloxacin, formulation, and dose (along with brand name if required)